.Attribute Medicine, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of individuals with HER2+ advanced breast cancer cells and energetic or even stable human brain metastases revealed regular intracranial task as well as systemic effectiveness of T-DXd.